Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075335 | 0.83 | HTR6 (0.58) | HTR6HRH3BCHE | |
| SCHEMBL4086941 | 0.78 | HDAC1 (0.54) | HTR6HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4076367 | 0.77 | HDAC1 (0.53) | HTR6HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL4312664 | 0.74 | HTR6 (0.69) | HTR6 | |
| SCHEMBL4082858 | 0.74 | HTR6 (0.45) | HTR6HRH3 | |
| SCHEMBL3152302 | 0.71 | HTR6 (0.87) | HTR6 | |
| SCHEMBL4081092 | 0.71 | HTR6 (0.55) | HTR6HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL3153544 | 0.71 | HTR6 (0.78) | HTR6 | |
| SCHEMBL31159516 | 0.68 | HDAC1 (0.76) | HTR6HDAC1HDAC3HDAC2HDAC6 | |
| SCHEMBL1793286 | 0.67 | PSMB1 (0.56) | ESR1ESR2HRH3NPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-09-24 | — | — | US | claimed |
| US-7541358-B2 | 1-Substituted indoles, benzimidazoles additionally substituted with an amino ligand, e.g., 1-[(5-chlorothien-2-yl)sulfonyl]-5-[2-(piperidin-1-yl)ethoxy]-1H-indole; treating schizophrenia, depression, attention deficit disorder, Alzheimer's disease and Parkinson's disease | WYETH (US) | 2009-06-02 | — | — | US | claimed |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | WYETH (US) | 2008-01-31 | — | — | US | claimed |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-13 | — | — | US | claimed |
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2009-09-24 | — | — | US | disclosed |
| US-7541358-B2 | 1-Substituted indoles, benzimidazoles additionally substituted with an amino ligand, e.g., 1-[(5-chlorothien-2-yl)sulfonyl]-5-[2-(piperidin-1-yl)ethoxy]-1H-indole; treating schizophrenia, depression, attention deficit disorder, Alzheimer's disease and Parkinson's disease | WYETH (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | WYETH (US) | 2008-01-31 | — | — | US | disclosed |
| US-7271180-B2 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239863-A1 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR1B, HTR1A | HTR6 1/4885HDAC1 904/4885HDAC3 790/4885 |
| US-20080027055-A1 | 1-Aryl-or 1-alkylsulfonnylbenzazole derivatives as 5-hydoxytryptamine-6 ligands | HTR6, HTR1B, HTR3B | HTR6 1/4885HDAC1 950/4885HDAC3 773/4885 |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | HTR6 1/4885HDAC1 904/4885HDAC3 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.